Cimetidine side effects gynecomastia is a well-recognised clinical concern for male patients taking this histamine H2-receptor antagonist. Cimetidine has been used for decades to manage peptic ulcer disease, GORD, and Zollinger-Ellison syndrome, but its weak anti-androgenic properties can disrupt the hormonal balance between testosterone and oestrogen, leading to benign breast tissue enlargement. Although proton pump inhibitors are now the preferred first-line treatment in UK practice, some patients remain on long-term cimetidine. This article explains the mechanism behind cimetidine-induced gynaecomastia, how common it is, when to seek medical advice, and what management options are available.

How Cimetidine Works and Its Known Side Effects

Cimetidine reduces gastric acid by blocking H2 receptors and also inhibits CYP450 enzymes and androgen receptors, causing hormonal side effects including gynaecomastia, galactorrhoea, and reduced libido.

Cimetidine is a histamine H2-receptor antagonist, a class of medicines that reduces the production of stomach acid by blocking H2 receptors on the parietal cells of the gastric lining. It has been used for decades to treat conditions such as peptic ulcer disease, gastro-oesophageal reflux disease (GORD), and Zollinger-Ellison syndrome. Newer acid-suppressing agents — particularly proton pump inhibitors (PPIs) — are now recommended as first-line therapy by NICE (NG1) for most acid-related conditions, and cimetidine is infrequently initiated in current UK clinical practice. However, some patients may still be taking it long-term.

Beyond its acid-suppressing action, cimetidine has several pharmacological properties that distinguish it from other H2 blockers. Notably, it inhibits cytochrome P450 (CYP450) enzymes in the liver — which can lead to clinically significant drug interactions — and it also has weak anti-androgenic activity, a property that underpins several of its hormonal side effects.

The recognised side effect profile of cimetidine includes:

• Gastrointestinal effects: diarrhoea, nausea, and constipation

• Central nervous system effects: headache, dizziness, and, rarely, confusion (particularly in elderly patients)

• Hepatic effects: transient rises in liver enzymes; rare cases of clinically significant hepatitis and cholestatic jaundice have also been reported

• Endocrine effects: gynaecomastia, galactorrhoea, and reduced libido — largely attributable to its anti-androgenic properties and, in some reported cases, effects on prolactin levels (though the precise prolactin-elevating mechanism is not fully established)

• Drug interactions: due to CYP450 inhibition, cimetidine can raise plasma levels of medicines including warfarin, phenytoin, and theophylline; this list is not exhaustive, and patients and clinicians should consult the BNF or a pharmacist for a comprehensive review of interactions

Understanding these mechanisms is important because the hormonal side effects of cimetidine, including gynaecomastia, arise directly from the drug's pharmacology and appear to be dose-dependent in nature. Authoritative information on adverse effects and interactions can be found in the BNF cimetidine monograph and the relevant UK Summary of Product Characteristics (SmPC).

How Common Is Gynaecomastia With Cimetidine?

Gynaecomastia is an uncommon but well-documented side effect of cimetidine, most frequently reported at high doses; it is generally reversible after stopping the drug.

Gynaecomastia — the benign enlargement of glandular breast tissue in males — is one of the more well-documented endocrine side effects associated with cimetidine use. It is considered an uncommon but recognised adverse effect, and its occurrence is closely linked to both the dose used and the duration of treatment. Published case series and clinical reports have described gynaecomastia particularly in patients receiving high-dose cimetidine therapy — for example, those treated for Zollinger-Ellison syndrome, where doses significantly exceed those used for standard ulcer management — though precise incidence figures vary across sources and readers should refer to the current UK SmPC or BNF for the most up-to-date frequency classification.

The mechanism is multifactorial. Cimetidine exerts weak antagonism at androgen receptors, effectively reducing the action of testosterone at the tissue level. It has also been reported to influence prolactin concentrations in some patients, although the evidence for this mechanism is based largely on case reports and the precise pathway remains uncertain. Together, these effects may shift the oestrogen-to-androgen ratio in favour of oestrogen, creating a hormonal environment that promotes gynaecomastia.

Gynaecomastia associated with cimetidine is generally reversible upon discontinuation of the drug. In most reported cases, breast tissue enlargement resolves within weeks to months after stopping treatment, provided no other contributing factors are present. However, in some individuals — particularly those with prolonged exposure — residual fibrous tissue may persist.

For context, famotidine — the H2 blocker most readily available in the UK — is not known to share cimetidine's anti-androgenic properties and is not typically associated with gynaecomastia. Ranitidine is no longer marketed in the UK following its withdrawal by the MHRA. Nizatidine has had limited and intermittent availability in the UK and should not be assumed to be a readily accessible alternative. This distinction is clinically relevant when selecting an appropriate acid-suppressing agent for male patients, particularly those already at risk of hormonal imbalance.

Recognising Symptoms and When to Seek Medical Advice

Cimetidine-induced gynaecomastia typically presents as a tender, palpable subareolar disc of tissue; hard, irregular, or fixed lumps, nipple discharge, or skin changes require urgent GP assessment.

Gynaecomastia caused by cimetidine typically presents as a palpable, often tender, disc of glandular tissue beneath one or both nipples. It may be unilateral or bilateral and is usually accompanied by breast tenderness or sensitivity. In some cases, patients may also notice mild swelling or a feeling of fullness in the chest area. These symptoms can develop gradually over weeks to months of treatment and may initially be subtle enough to go unnoticed.

It is important to distinguish drug-induced gynaecomastia from other causes of breast changes in men, including:

• Pseudogynaecomastia: fatty tissue deposition without true glandular enlargement (no firm subareolar disc of tissue), commonly associated with obesity

• Breast malignancy: rare in men but must be excluded — see red-flag features below

• Other drug causes: spironolactone, anabolic steroids, some antipsychotics, and certain antihypertensives are also associated with gynaecomastia

• Underlying conditions: liver disease, hypogonadism, hyperthyroidism, and testicular tumours can all cause gynaecomastia independently

When to seek urgent medical advice

Patients should seek prompt assessment from their GP if they notice any new breast swelling, lump, or nipple discharge whilst taking cimetidine. Certain features require urgent evaluation and may warrant referral via the NHS 2-week suspected cancer pathway (in line with NICE NG12: Suspected Cancer: Recognition and Referral). These red-flag features include:

• A hard, irregular, or fixed lump in the breast

• Unilateral nipple discharge (particularly bloodstained)

• Skin changes over the breast (such as dimpling, puckering, or ulceration)

• Nipple retraction or inversion

• Swollen lymph nodes in the axilla

• Any associated testicular mass or systemic symptoms

Whilst drug-induced gynaecomastia is generally benign, a clinical assessment is necessary to rule out more serious pathology. Referral to an endocrinologist or breast clinic may be warranted depending on the clinical findings. Patients should not stop taking cimetidine abruptly without first consulting their prescriber, particularly if it is being used to manage an active gastrointestinal condition.

Managing Gynaecomastia: Dose Adjustment and Alternatives

Switching from cimetidine to a PPI or famotidine is the preferred management strategy; gynaecomastia usually resolves within one to six months of stopping cimetidine.

When gynaecomastia is identified as a likely consequence of cimetidine therapy, the first step in management is a thorough clinical review by the prescribing clinician. In many cases, reducing the dose of cimetidine — where clinically appropriate — may help to alleviate symptoms, given the dose-dependent nature of this side effect. However, if symptoms are significant or persistent, switching to an alternative acid-suppressing agent is usually the preferred approach.

For most patients requiring ongoing acid suppression, the following alternatives carry a substantially lower risk of hormonal side effects:

• Proton pump inhibitors (PPIs): omeprazole, lansoprazole, and pantoprazole are the first-line agents recommended by NICE (NG1) for conditions such as GORD and peptic ulcer disease. PPIs are not typically associated with gynaecomastia, though rare individual case reports exist; they remain the most appropriate switch for the majority of patients

• Other H2 blockers: famotidine is the most readily available H2 blocker in the UK and is not known to have anti-androgenic properties. Ranitidine is no longer available in the UK (withdrawn by the MHRA); nizatidine has limited UK availability and should not be assumed to be accessible

In the majority of cases, gynaecomastia resolves spontaneously following discontinuation of cimetidine, typically within one to six months, though fibrotic changes may take longer to fully resolve. Patients should be reassured that gradual improvement is the expected course. If breast tissue enlargement has not improved after approximately six months following cessation of the drug — or sooner if any red-flag features develop — further investigation is advisable to exclude other contributing causes.

In rare cases where gynaecomastia is longstanding, causes significant psychological distress, or has resulted in persistent fibrous tissue, referral to a specialist — such as an endocrinologist or plastic surgeon — may be considered. Surgical intervention (subcutaneous mastectomy) is occasionally performed in refractory cases, though this is rarely necessary when the causative drug is identified and withdrawn promptly. Clinicians should also consult NICE CKS guidance on gynaecomastia and male breast symptoms for primary care assessment and referral recommendations.

MHRA Guidance and Discussing Options With Your GP

Gynaecomastia is listed in cimetidine's UK SmPC; patients should speak to their GP before changing medication and report suspected reactions via the MHRA Yellow Card scheme.

Gynaecomastia is a recognised adverse effect of cimetidine, as reflected in the drug's UK Summary of Product Characteristics (SmPC) and the BNF. Healthcare professionals and patients are encouraged to report suspected adverse drug reactions — including gynaecomastia — through the MHRA's Yellow Card scheme (available at yellowcard.mhra.gov.uk). Reporting helps regulators monitor the real-world safety profile of medicines and identify any emerging signals that may not have been apparent in clinical trials.

NICE guidance (NG1) supports the use of PPIs as first-line therapy for the majority of acid-related conditions, including GORD, peptic ulcer disease, and dyspepsia. Given this guidance, cimetidine is now infrequently initiated as a new treatment in UK clinical practice. However, some patients may still be taking it long-term, particularly if it was prescribed before current guidelines were established. Cimetidine is not currently available as a licensed over-the-counter product in the UK, and patients should not be obtaining it without medical supervision.

If you are taking cimetidine and have concerns about gynaecomastia or other side effects, it is important to:

• Speak to your GP before making any changes to your medication

• Bring a list of all medicines you are currently taking, including any over-the-counter products and supplements, as other agents may also contribute to hormonal changes

• Ask about alternatives — your GP can advise whether switching to a PPI or famotidine would be appropriate for your condition

• Report side effects via the Yellow Card scheme (yellowcard.mhra.gov.uk) if you believe cimetidine has caused an adverse reaction

Useful sources of further information include the NHS page on gynaecomastia, NICE NG12 for guidance on when breast symptoms in men require urgent assessment, and the BNF for comprehensive prescribing information. Open communication with your healthcare team is the most effective way to manage side effects safely whilst ensuring your underlying condition continues to be treated appropriately.

Frequently Asked Questions